Form 4 for TGTX TG THERAPEUTICS, INC.
Accepted 2022-07-22 00:00:00 ET · period of report 2022-07-20 · accession 0001104659-22-082024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-22 | 2022-07-20 | TGTX | Power Sean A | CFO | A - Grant | $0.00 | +75.0K | 643.5K | +13% | $0 |
| D | 2022-07-22 | 2022-07-20 | TGTX | Power Sean A | CFO | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-20 | A | A | 75,000 | $0.00 | 643,483 | D | — | — | (F1) Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab. (F2) Includes shares of restricted Common Stock, which vest over various time periods. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-07-20 | A | A | 200,000 | $0.00 | 200,000 | D | $7.00 · — to 2027-07-20 | 200,000 Common Stock, par value $0.001 | (F3) Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis. |